Lunit and Summit announce SCOPE IO research agreement
Source publication date
Site published
SCOPE IO will analyze H&E slides for ivonescimab tumor-microenvironment research.
Announced October 23; page dated October 24; checked October 24, 2026.
Source: https://www.lunit.io/en/media-hub/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development/
Summary
An agreement to evaluate pathology AI in drug research.
Editorial view
Editorial view: distinguish research collaboration from clinical deployment.
Evidence and limitations
Research-only; no diagnostic clearance or clinical outcomes announced. Value undisclosed.